Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPARD | Q03181 | 4/20 | 0.34 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442342 | 0.92 | LMNA (0.45) | TSHRLMNAALDH1A1CYP1A2 | |
| SCHEMBL6441150 | 0.88 | EGLN1 (0.42) | TSHRLMNACYP1A2VCAM1 | |
| SCHEMBL28342492 | 0.88 | LMNA (0.50) | TSHRLMNAALDH1A1CYP1A2MEN1 | |
| SCHEMBL6441153 | 0.83 | LMNA (0.39) | TSHRLMNA | |
| SCHEMBL20051869 | 0.82 | LMNA (0.55) | TSHRLMNAALDH1A1CYP1A2MEN1 | |
| SCHEMBL10010461 | 0.81 | TSHR (0.43) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL19500201 | 0.81 | LMNA (0.40) | TSHRLMNAALDH1A1 | |
| SCHEMBL756970 | 0.81 | LMNA (0.63) | TSHRLMNAALDH1A1CYP1A2MEN1 | |
| SCHEMBL10553643 | 0.80 | TSHR (0.54) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL18620 | 0.79 | LMNA (0.61) | TSHRSLC22A6LMNANFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | disclosed |
| US-6432931-B1 | NITROGEN CONTAINING BISPHOSPHONATE COMPOUND | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | disclosed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | TSHR 1887/4885SLC22A6 471/4885LMNA 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.